For over fifty years, the cannabis industry has operated under a 1970s-era classification that designated marijuana as dangerous as heroin and LSD. This regulatory wall has finally begun to crumble. In a historic move that defines the most significant federal drug policy update in half a century, the U.S. Department of Justice (DOJ) has officially issued a final order to reschedule parts of marijuana use.
Following President Trump’s December 18, 2025, Executive Order on Increasing Medical Marijuana and Cannabidiol Research, the DOJ and the DEA have moved with unprecedented speed. Effective immediately, marijuana products subject to a qualifying state medical license and FDA-approved marijuana drugs have been placed in Schedule III of the Controlled Substances Act.
The Core News: What Just Changed?
The announcement by Acting Attorney General Todd Blanche is two-pronged. It provides immediate relief for the medical sector while setting a definitive clock for the rest of the industry.
- Immediate Rescheduling: FDA-approved drug products and products regulated by a state medical marijuana license are now officially Schedule III.
- The June 29, 2026 Hearing: The DOJ has initiated an expedited administrative hearing process to consider the broader rescheduling of all marijuana from Schedule I to Schedule III.
By categorizing medical marijuana alongside substances like Tylenol with Codeine, the federal government is finally acknowledging what millions of patients and 38 states already knew: marijuana has clear medical benefits.
At Proven Media, we have spent years navigating the complex intersection of cannabis policy and public perception. This news represents a fundamental shift in the American economic, medical, and scientific landscape that will unlock doors for growth, innovation, and research.
Why This Matters
For businesses, the most immediate win is the effective elimination of IRS Code Section 280E. Under Schedule I, cannabis operators were legally classified as traffickers, prohibiting them from deducting standard business expenses like rent, payroll, and marketing. This resulted in effective tax rates as high as 70%.
With the move to Schedule III, Section 280E no longer applies to medical operations. This will allow medical businesses to finally operate like a traditional American company, reinvesting capital into their employees, facilities, and communities. Furthermore, the Department of the Treasury is currently evaluating retrospective relief, which could potentially allow businesses to file refund claims for prior years, a move that could return billions of dollars in liquidity to the sector.
What the News Is and Isn’t
As an agency specializing in industry communications, we know that clarity is the best tool against misinformation. While this is a watershed moment, it’s important to understand the current boundaries of the law.
What It IS:
- A Scientific Green Light: By slashing federal red tape, researchers can finally study the plant’s benefits without the Catch-22 of Schedule I restrictions.
- Federal Validation: The US government officially confirms the plant has medical utility.
- A Pathway to Professionalism: The order establishes an expedited DEA registration pathway for holders of state medical licenses, bringing a new level of oversight and consistency to the market.
What It IS NOT:
- Federal Legalization: Adult-use remains a schedule three classification
- Criminal Justice Reform: This order does not automatically release federal prisoners or expunge past records. These remain separate legislative battles.
- Interstate Commerce: It remains illegal to transport the plant across state lines. T
Looking Ahead to June
By withdrawing prior notices and terminating old proceedings from previous administrations, the current DEA is moving with consistency and oversight.
The upcoming hearing on June 29, 2026, will be the definitive arena where the fate of all cannabis, beyond compliant medical use, is decided.
| Key Feature | Previous Status (Schedule I) | New Status (Schedule III – Medical) |
| Medical Utility | None recognized by Feds | Officially Recognized |
| Tax Treatment | 280E Penalties (70%+ rates) | Normal Business Deductions |
| Medical Research | Extremely restricted | Green-lit and Encouraged |
| Federal Oversight | Law Enforcement priority | Administrative Consistency |
A New Standard of Legitimacy
The move to Schedule III for medical marijuana brings the industry from the fringes of the economy toward the mainstream. It is a moment of validation for the state-regulated programs that have pioneered safety and quality standards in the absence of federal guidance.
As Acting Attorney General Blanche noted, this is about providing “doctors with more reliable information” and “patients with better care.” For operators, the transition brings new requirements: DEA registration portals are opening April 29th, 2026, and compliance with federal reporting will become a standard of doing business.
The conversation has shifted from if cannabis belongs in the American medicine cabinet to how we can best ensure it is safe, accessible, and fairly taxed.
The future of cannabis is medical, professional, and finally being treated with the legal logic it deserves. As we look toward the June 2026 hearings, the industry stands ready to prove that when given a level playing field, cannabis can be one of the most vibrant sectors of the American economy.
Preparing for Federal Registration: Requirements and Timelines
For medical marijuana dispensaries, the federal registration process is the next critical step in formalizing operations under the new DOJ framework.
The DEA registration portal is scheduled to open on Wednesday, April 29, 2026, at 9:00 AM EST. To ensure a seamless application, operators should have the following documentation and data ready for the seven-section filing:
Application Requirements Overview
- Business & Ownership Data: Legal name, Tax ID (SSN/EIN), and a 12-month history of any ownership changes.
- Specific Activity Codes: Applicants must identify the specific drug codes they handle: 7362 (Marijuana), 7353 (Marijuana Extract), or 7386 (Naturally derived delta-9-THC).
- State Licensing: Current state license numbers, issuing authority, and expiration dates are mandatory for the “qualifying state medical license” exemption.
- Liability Disclosures: Comprehensive history regarding any past controlled substance crimes, surrendered registrations, or disciplinary actions involving officers, partners, or stockholders.
- Compliance & SOPs: The DEA requires confirmation of Standard Operating Procedures (SOPs) for inventories, storage, security, dispensing, and theft/loss reporting.
- Personnel Backgrounds: Full identifying information (Name, DOB, SSN) for every individual who will have access to controlled substances.
- Facility Security: Specific details on physical security measures, including vaults, safes, and access control systems (fobs/biometrics).
Applicants should note that PayPal is currently the only accepted form of payment for registration fees, which are non-refundable.
While the broader industry awaits the outcome of the June 29 hearings, the opening of this portal represents the first tangible step toward federal integration for the medical sector. Proper preparation for this filing is essential to avoid administrative delays and ensure full compliance with the new federal standards.
